On July 24, 2026, the Centers for Medicare & Medicaid Services (CMS) published a Federal Register notice initiating a 60-day public comment period for two critical information collection efforts. These proposals are integral to the agency's responsibilities under the Paperwork Reduction Act (PRA) of 1995 and directly impact the implementation of the Inflation Reduction Act's (IRA) drug price negotiation provisions and the foundational operations of the Medicare Part D prescription drug program. The announcement signals a vital opportunity for stakeholders across the healthcare industry to influence federal data requirements that underpin significant Medicare functions.
Background on Information Collection and PRA
Federal agencies routinely collect information from the public to fulfill their statutory mandates. The PRA serves as a crucial regulatory framework, requiring agencies like CMS to seek public input and obtain approval from the Office of Management and Budget (OMB) before imposing information collection requirements. This process ensures that data collections are necessary, minimize burden, and are designed for maximum utility and clarity. The current notice from CMS exemplifies this process, inviting comments on the necessity, accuracy of burden estimates, and potential improvements for the proposed data collections.
CMS-10912: The Medicare Transaction Facilitator (MTF) and Drug Price Negotiation
This first information collection request, identified as CMS-10912, focuses on revisions to the Medicare Transaction Facilitator (MTF) system, a key component stemming from Sections 11001 and 11002 of the Inflation Reduction Act. The IRA empowered Medicare to negotiate prices for certain high-cost prescription drugs, a landmark policy shift aimed at lowering drug costs for beneficiaries and the federal government.
The MTF is designed with two primary functionalities: the MTF Data Module (DM) and the MTF Payment Module (PM). While participation in the MTF PM is voluntary for Primary Manufacturers and acts as a pass-through mechanism for transferring funds, participation in the MTF DM is mandatory. Primary Manufacturers with active Medicare Drug Price Negotiation Program Agreements are required to engage with the MTF DM. CMS intends to leverage existing information from these manufacturers to establish their access to the platform.
Under sections 1193(a)(5) and 1196 of the Act, CMS is authorized to collect data essential for negotiation administration and compliance monitoring. The MTF DM serves as an IT platform facilitating the transmission of claims and payment data among Primary Manufacturers, the MTF DM, the MTF PM, Part B providers, and dispensing entities. This data exchange is crucial for the effectuation of manufacturer price reductions (MFP) for Medicare beneficiaries. Beyond facilitation, the MTF also functions as a central repository for oversight, allowing CMS to monitor MFP access and manage complaints or disputes.
The burden associated with this collection is estimated to affect 73,925 respondents, primarily private sector businesses and for-profits, with a total annual burden of 274,980 hours. This reflects the significant operational adjustments and data reporting requirements for pharmaceutical manufacturers involved in the IRA's drug negotiation program.
CMS-10174: Collection of Prescription Drug Event (PDE) Data for Part D Payments
The second request, CMS-10174, pertains to the ongoing and critical collection of Prescription Drug Event (PDE) data from contracted Medicare Part D providers. This data collection is fundamental to the accurate and efficient operation of the entire Medicare Part D program, which provides outpatient prescription drug coverage to millions of beneficiaries.
CMS emphasizes its commitment to the least burdensome data submission requirements, asserting that claims-level data is indispensable for verifying the accuracy of Part D payments. Without this detailed information, CMS states it cannot adequately calculate payments related to reinsurance, risk corridors, low-income subsidies, Coverage Gap Discount Program (CGDP) reconciliation, Medicare Discount Program (MDP) reconciliation, and the Inflation Reduction Act Subsidy Adjustment (IRASA), among other functions.
Part D sponsors, including pharmacy benefit managers (PBMs), third-party administrators, pharmacies, Prescription Drug Plans (PDPs), Medicare Advantage Prescription Drug Plans (MA-PDs), and other plans offering Part D coverage, are responsible for reporting this claims-level information via the PDE record. CMS restricts data collection to only those elements critical for accurate payment calculations, along with others necessary for PDE record validation, quality monitoring, and robust program integrity and oversight. Furthermore, PDE data supports broader operational needs and program development initiatives.
The scope of this collection is substantial, involving 994 respondents but generating an astounding 1,627,799,680 total annual responses, accounting for 11,208 total annual hours. This volume underscores the vast number of prescription drug claims processed under Medicare Part D annually and the critical nature of this data for financial management and program accountability.
Implications for Stakeholders
For pharmaceutical manufacturers, particularly those with drugs subject to IRA negotiation, the MTF system represents a complex new layer of compliance and data submission. It mandates transparency and participation in the MFP effectuation process, directly linking manufacturer actions to beneficiary savings. The accuracy and efficiency of this system will be paramount for both industry and government.
Part D sponsors and providers face continued, extensive data reporting requirements through the PDE system. While an existing collection, its continued necessity highlights the intricate financial mechanics of Part D. Any changes to data elements or reporting mechanisms could have significant operational impacts on these entities, affecting claims processing, payment accuracy, and compliance.
Ultimately, the functionality and integrity of both systems are crucial for Medicare beneficiaries. The MTF ensures that the negotiated drug prices translate into real savings at the pharmacy counter. The PDE data collection ensures the financial stability and proper administration of their Part D benefits, affecting everything from their monthly premiums to their out-of-pocket costs.
Opportunity for Public Comment
The 60-day comment period, ending September 22, 2026, provides a vital window for all affected parties to voice their perspectives. This includes pharmaceutical companies, Part D plan sponsors, pharmacists, healthcare providers, patient advocacy groups, and other interested members of the public. Comments can address the practicalities of data submission, the estimated burden, the clarity of instructions, and whether the proposed collections are truly necessary and efficient for CMS to achieve its goals under the IRA and Part D program. Engaging in this process is critical for shaping federal policies and operational procedures that will have lasting effects on the nation's healthcare landscape.
